Specific Substitutions in Region V2 of gp120

AIDS CCR5 Env HIV Rhesus macaque SHIV V2 region mutagenesis

Journal

Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317

Informations de publication

Date de publication:
03 Mar 2020
Historique:
received: 08 02 2020
revised: 25 02 2020
accepted: 26 02 2020
entrez: 7 3 2020
pubmed: 7 3 2020
medline: 7 3 2020
Statut: epublish

Résumé

A tier 2 SHIV-MK38 strain was obtained after two in vivo passages of tier 1 SHIV-MK1. SHIV-MK38#818, cloned from the MK38 strain, was neutralisation-resistant, like the parental MK38 strain, to SHIV-infected monkey plasma (MP), HIV-1-infected human pooled plasma (HPP), and KD247 monoclonal antibody (mAb) (anti-V3 gp120

Identifiants

pubmed: 32138199
pii: pathogens9030181
doi: 10.3390/pathogens9030181
pmc: PMC7157653
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Scientific Research (B) from the Japan Society for the Promotion of Science
ID : 16H04682
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP18fk0410011, JP18fk0410002, JP18fk0410013

Références

J Virol. 2006 Jun;80(11):5563-70
pubmed: 16699037
J Virol. 1996 Feb;70(2):1100-8
pubmed: 8551569
J Virol. 2008 Jan;82(2):638-51
pubmed: 17959660
Mol Cell Biol. 1987 Jan;7(1):379-87
pubmed: 3031469
J Virol. 2014 Sep 1;88(17):10177-88
pubmed: 24965454
Sci Adv. 2018 Nov 21;4(11):eaau6769
pubmed: 30474059
J Virol. 1998 Apr;72(4):2855-64
pubmed: 9525605
Nature. 2011 Nov 23;480(7377):336-43
pubmed: 22113616
J Virol. 1991 Jul;65(7):3514-20
pubmed: 2041078
J Virol. 1996 Oct;70(10):6922-8
pubmed: 8794335
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
J Gen Virol. 2016 May;97(5):1249-1260
pubmed: 26850058
Retrovirology. 2008 Jan 31;5:10
pubmed: 18237398
J Virol. 2010 Feb;84(3):1439-52
pubmed: 19939925
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
J Virol. 2010 Oct;84(20):10863-76
pubmed: 20702642
Structure. 2015 Jun 2;23(6):1138-49
pubmed: 26039348
Curr Opin HIV AIDS. 2018 Mar;13(2):128-136
pubmed: 29266013
J Gen Virol. 1999 May;80 ( Pt 5):1231-1240
pubmed: 10355770
PLoS Pathog. 2019 Jul 15;15(7):e1007920
pubmed: 31306470
AIDS. 1996 Jun;10(6):587-93
pubmed: 8780812
Virology. 2010 Mar 30;399(1):134-143
pubmed: 20102777
Virol Sin. 2016 Jun;31(3):207-18
pubmed: 27117672
Retrovirology. 2013 Feb 06;10:14
pubmed: 23384254
Virology. 2015 Jan 15;475:187-203
pubmed: 25486586
PLoS One. 2014 Jan 21;9(1):e86083
pubmed: 24465884
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
J Biol Chem. 2019 Apr 5;294(14):5616-5631
pubmed: 30728245
J Virol. 2006 Jun;80(11):5552-62
pubmed: 16699036

Auteurs

Yalcin Pisil (Y)

Laboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Kyoto University, Kyoto 615-8530, Japan.

Zafer Yazici (Z)

Department of Virology, Faculty of Veterinary Medicine, 19 Mayis University, Samsun 55270, Turkey.

Hisatoshi Shida (H)

Division of Molecular Virology, Institute of Immunological Science, Hokkaido University, Hokkaido 060-0808, Japan.

Shuzo Matsushita (S)

Center for AIDS Research, Kumamoto University, Kumamoto 860-8555, Japan.

Tomoyuki Miura (T)

Laboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Kyoto University, Kyoto 615-8530, Japan.

Classifications MeSH